Acorah Software Products - Accounts Production 15.0.500 false true 31 March 2023 1 April 2022 false 1 April 2023 31 March 2024 31 March 2024 08323531 Mr Robert Baggott Mr William Barclay Mr Richard Rowe Mrs Kate Sneddon Mr Benjamin Charles Mr Graham Wilkins Biovault Scientific Ltd true iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 08323531 2023-03-31 08323531 2024-03-31 08323531 2023-04-01 2024-03-31 08323531 frs-core:Non-currentFinancialInstruments 2024-03-31 08323531 frs-core:BetweenOneFiveYears 2024-03-31 08323531 frs-core:WithinOneYear 2024-03-31 08323531 frs-core:ShareCapital 2024-03-31 08323531 frs-core:RetainedEarningsAccumulatedLosses 2024-03-31 08323531 frs-bus:PrivateLimitedCompanyLtd 2023-04-01 2024-03-31 08323531 frs-bus:AbridgedAccounts 2023-04-01 2024-03-31 08323531 frs-bus:SmallEntities 2023-04-01 2024-03-31 08323531 frs-bus:AuditExempt-NoAccountantsReport 2023-04-01 2024-03-31 08323531 frs-bus:SmallCompaniesRegimeForAccounts 2023-04-01 2024-03-31 08323531 1 2023-04-01 2024-03-31 08323531 frs-bus:Director1 2023-04-01 2024-03-31 08323531 frs-bus:Director2 2023-04-01 2024-03-31 08323531 frs-bus:Director3 2023-04-01 2024-03-31 08323531 frs-bus:Director4 2023-04-01 2024-03-31 08323531 frs-bus:Director5 2023-04-01 2024-03-31 08323531 frs-bus:CompanySecretary1 2023-04-01 2024-03-31 08323531 frs-countries:EnglandWales 2023-04-01 2024-03-31 08323531 2022-03-31 08323531 2023-03-31 08323531 2022-04-01 2023-03-31 08323531 frs-core:Non-currentFinancialInstruments 2023-03-31 08323531 frs-core:BetweenOneFiveYears 2023-03-31 08323531 frs-core:WithinOneYear 2023-03-31 08323531 frs-core:ShareCapital 2023-03-31 08323531 frs-core:RetainedEarningsAccumulatedLosses 2023-03-31
Registered number: 08323531
Biovault Technical Limited
Unaudited ABRIDGED Financial Statements
For The Year Ended 31 March 2024
Contents
Page
Abridged Balance Sheet 1—2
Notes to the Abridged Financial Statements 3—5
Page 1
Abridged Balance Sheet
Registered number: 08323531
2024 2023
Notes £ £ £ £
CURRENT ASSETS
Stocks 19,233 18,750
Debtors 355,705 330,002
Cash at bank and in hand 340,740 127,646
715,678 476,398
Creditors: Amounts Falling Due Within One Year (601,240 ) (785,473 )
NET CURRENT ASSETS (LIABILITIES) 114,438 (309,075 )
TOTAL ASSETS LESS CURRENT LIABILITIES 114,438 (309,075 )
Creditors: Amounts Falling Due After More Than One Year - (43,333 )
NET ASSETS/(LIABILITIES) 114,438 (352,408 )
CAPITAL AND RESERVES
Called up share capital 5 135,000 135,000
Profit and Loss Account (20,562 ) (487,408 )
SHAREHOLDERS' FUNDS 114,438 (352,408)
Page 1
Page 2
For the year ending 31 March 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
All of the company's members have consented to the preparation of an Abridged Profit and Loss Account and an Abridged Balance Sheet for the year end 31 March 2024 in accordance with section 444(2A) of the Companies Act 2006.
On behalf of the board
Mr Robert Baggott
Director
30th July 2024
The notes on pages 3 to 5 form part of these financial statements.
Page 2
Page 3
Notes to the Abridged Financial Statements
1. General Information
Biovault Technical Limited is a private company, limited by shares, incorporated in England & Wales, registered number 08323531 . The registered office is 24 Brest Road, Plymouth, Devon, PL6 5XP.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
2.2. Turnover
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover is reduced for estimated customer returns, rebates and other similar allowances.
Sale of goods
Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods has transferred to the buyer. This is usually at the point that the customer has signed for the delivery of the goods.
Rendering of services
Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.
2.3. Stocks and Work in Progress
Stocks and work in progress are valued at the lower of cost and net realisable value after making due allowance for obsolete and slow-moving stocks. Cost includes all direct costs and an appropriate proportion of fixed and variable overheads. Work-in-progress is reflected in the accounts on a contract by contract basis by recording turnover and related costs as contract activity progresses.
2.4. Foreign Currencies
Monetary assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction. Exchange differences are taken into account in arriving at the operating profit.
2.5. Taxation
Income tax expense represents the sum of the tax currently payable and deferred tax.
The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the statement of comprehensive income because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.
...CONTINUED
Page 3
Page 4
2.5. Taxation - continued
Deferred tax is recognised on timing differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable timing differences. Deferred tax assets are generally recognised for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible timing differences can be utilised. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.
Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. Deferred tax liabilities are presented within provisions for liabilities and deferred tax assets within debtors. The measurement of deferred tax liabilities and assets reflect the tax consequences that would follow from the manner in which the Company expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.
Current or deferred tax for the year is recognised in profit or loss, except when they related to items that are recognised in other comprehensive income or directly in equity, in which case, the current and deferred tax is also recognised in other comprehensive income or directly in equity respectively.
3. Average Number of Employees
Average number of employees, including directors, during the year was: 10 (2023: 6)
10 6
4. Secured Creditors
Of the creditors falling due within and after more than one year the following amounts are secured. The security provided is a fixed and floating charge over the company's assets. 
2024 2023
£ £
Bank loans and overdrafts - 63,333
5. Share Capital
2024 2023
£ £
Allotted, Called up and fully paid 135,000 135,000
6. Other Commitments
The total of future minimum lease payments under non-cancellable operating leases are as following:
2024 2023
£ £
Not later than one year 12,752 1,108
Later than one year and not later than five years 2,216 2,216
14,968 3,324
Page 4
Page 5
7. Related Party Transactions
The company uses fixed assets and intellectual property which is owned by its parent company, Biovaut Scientific Ltd. It also jointly uses premises which are leased by its parent company. During the period, the company has allowed for a management charge of £325,000 (2023  - £125,000) from its parent company to cover the uses of such items. 
Included within Consultancy fees is £9,690 (2023 - £3,240) invoiced by one of the directors K Sneddon.
8. Ultimate Controlling Party
The company's ultimate controlling party is Biovault Scientific Ltd by virtue of its ownership of 100% of the issued share capital in the company. Biovault Scientific Ltd is a company incorporated in England and Wales. Copies of its accounts can be obtained from Companies House, Crown Way, Cardiff CF14 3UZ
Page 5